Alector (ALEC) Price & Analysis

Compare

488 Followers

ALEC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.87 - $6.37

Previous CloseN/A

Volume194.31K

Average Volume (3M)1.08M

Market Cap

$227.73M

Enterprise Value-$127.28M

Total Cash (Recent Filing)$307.28M

Total Debt (Recent Filing)$39.48M

Price to Earnings (P/E)―

Beta2.21

Next Earnings

Nov 11, 2025

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding101,212,326

10 Day Avg. Volume2,272,960

30 Day Avg. Volume1,075,280

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.56

Enterprise Value/Revenue-1.57

Enterprise Value/Gross Profit-4.05

Enterprise Value/Ebitda0.99

Forecast

1Y Price Target

$3.80

Price Target Upside68.89% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Efficacy DataThe AL001-treated cohort demonstrated a 48% reduction in the annual progression rate of CDR plus NACC FTLD-SB scores compared to matched GENFI controls, reinforcing the potential efficacy of the treatment.

Financial Stability$307 million cash will last into the second half of 2027, providing a strong financial runway.

Trial DesignThe study is >99% powered for the new co-primary endpoint, and prior open-label data showed normalization of both plasma and CSF PGRN, providing confidence that this endpoint will be met.

Bears Say

Discontinued ProgramsDisappointing INVOKE-2 data for the now-discontinued AL002 in Alzheimer’s disease.

Regulatory RequirementsFDA requested an additional co-primary endpoint in the INFRONT-3 study, reflecting interest in understanding the drug's mechanistic efficacy.

Alector News

Alector sees FY25 revenue view $13M-$18M, consensus $12.56M

The company said, “Management is updating its guidance for the year ending 2025. The company anticipates collaboration revenue...

10d ago

ALEC

Alector reports Q2 EPS (30c), consensus (47c)

Reports Q2 revenue $7.87M, consensus $2.8M. “The topline results from the pivotal INFRONT-3 Phase 3 trial of latozinemab,...

10d ago

ALEC

Alector upgraded to Outperform from Neutral at Mizuho

Mizuho upgraded Alector (ALEC) to Outperform from Neutral with a price target of $3.50, up from $2.50. With...

21d ago

ALEC

Alector’s Earnings Call: Progress and Challenges in Neurodegenerative Treatments

Alector (($ALEC)) has held its Q2 earnings call. Read on for the main highlights of the call. Alector’s...

5d ago

ALEC

Promising Advancements in Alector’s Clinical Trials Highlighted by Positive Biomarker Data and Therapeutic Potential

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector, retaining the price target of $10.00....

9d ago

ALEC

Alector Advances Neurodegenerative Therapies Amid Financial Updates

Alector ( ($ALEC) ) has released its Q2 earnings. Here is a breakdown of the information Alector presented...

10d ago

ALEC

Promising Developments and Strong Financials Make Alector a Compelling Buy

TD Cowen analyst Yaron Werber has maintained their bullish stance on ALEC stock, giving a Buy rating yesterday....

10d ago

ALEC

Alector’s Promising Future: Buy Rating Backed by Strategic Trials and FDA-Endorsed Amendments

William Blair analyst Myles Minter has maintained their bullish stance on ALEC stock, giving a Buy rating on...

10d ago

ALEC

Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment

Alector (($ALEC)) announced an update on their ongoing clinical study. Study Overview: Alector Inc. is conducting a continuation...

16d ago

ALEC

Alector Announces CFO Resignation and Interim Appointment

Alector ( ($ALEC) ) just unveiled an update. On June 9, 2025, Alector announced the resignation of its...

2M ago

ALEC

Alector CFO Marc Grasso to depart, Neil Berkley appointed Interim CFO

Alector (ALEC) announced that its CFO, Marc Grasso, M.D., will conclude his tenure with the company, effective June...

2M ago

ALEC

Alector Reports Increased Loss, Advances Clinical Pipeline

Alector ( ($ALEC) ) has released its Q1 earnings. Here is a breakdown of the information Alector presented...

3M ago

ALEC

Alector price target raised to $10 from $7 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Alector (ALEC) to $10 from $7 and...

3M ago

ALEC

Alector’s Growth Potential Highlighted by Strong Financials and Promising Trial Developments

TD Cowen analyst Yaron Werber has maintained their bullish stance on ALEC stock, giving a Buy rating today....

3M ago

ALEC

ALEC FAQ

What was Alector Inc’s price range in the past 12 months?

Alector Inc lowest stock price was $0.87 and its highest was $6.37 in the past 12 months.

What is Alector Inc’s market cap?

Alector Inc’s market cap is $227.73M.

When is Alector Inc’s upcoming earnings report date?

Alector Inc’s upcoming earnings report date is Nov 11, 2025 which is in 85 days.

How were Alector Inc’s earnings last quarter?

Alector Inc released its earnings results on Aug 07, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.461 by $0.161.

Is Alector Inc overvalued?

According to Wall Street analysts Alector Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alector Inc pay dividends?

Alector Inc does not currently pay dividends.

What is Alector Inc’s EPS estimate?

Alector Inc’s EPS estimate is -0.41.

How many shares outstanding does Alector Inc have?

Alector Inc has 101,212,326 shares outstanding.

What happened to Alector Inc’s price movement after its last earnings report?

Alector Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.461. Following the earnings report the stock price went up 47.26%.

Which hedge fund is a major shareholder of Alector Inc?

Currently, no hedge funds are holding shares in ALEC

Alector Stock Smart Score

Underperform

Fundamentals

Return on Equity

-103.98%

Trailing 12-Months

Asset Growth

-37.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alector Inc

Alector (ALEC) is a biotechnology company focused on developing immuno-neurology therapeutics to treat neurodegenerative diseases such as Alzheimer's and other related conditions. By leveraging its proprietary platform, Alector aims to harness the immune system to target and modify the underlying biology of these diseases, with a commitment to addressing significant unmet medical needs. The company's pipeline includes several clinical-stage programs and collaborations aimed at advancing innovative treatments.

Alector (ALEC) Earnings & Revenues

Historic Earnings Reports

ALEC Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant advancements in Alector's clinical trials and collaborations, particularly with GSK, for developing treatments for neurodegenerative diseases. However, challenges remain in addressing the unmet needs in frontotemporal dementia and navigating complex regulatory requirements.View all ALEC earnings summaries

ALEC Stock 12 Month Forecast

Average Price Target

$3.80

▲(68.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,2.1076923076923078,2.7653846153846153,3.4230769230769234,4.080769230769231,4.738461538461539,5.3961538461538465,6.0538461538461545,6.711538461538463,7.369230769230771,8.026923076923078,8.684615384615386,9.342307692307694,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.6307692307692307,1.8115384615384613,1.9923076923076921,2.173076923076923,2.3538461538461535,2.5346153846153845,2.715384615384615,2.8961538461538456,3.0769230769230766,3.2576923076923077,3.438461538461538,3.619230769230769,{"y":3.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.4153846153846152,1.3807692307692307,1.346153846153846,1.3115384615384615,1.2769230769230768,1.2423076923076923,1.2076923076923076,1.1730769230769231,1.1384615384615384,1.103846153846154,1.0692307692307692,1.0346153846153845,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >